netFormulary NHS
Nottinghamshire Area Prescribing Committee
Joint Formulary
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Chapter Links...
 Details...
06.01.02.03  Expand sub section  Other antidiabetic drugs
06.01.02.03  Expand sub section  Alpha glucosidase inhibitors
06.01.02.03  Expand sub section  DPP4 inhibitors (gliptins)
06.01.02.03  Expand sub section  GLP1 agonists
Lixisenatide (Lyxumia)
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 2

Subcutaneous injection

 
Link  Independent review
   
Dulaglutide (Trulicity)
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 2
  • Note: Ready made. No requirement to reconstitute powder.
 
Link  Link to reviews
Link  NICE: Evidence Summary (ESNM59)
Link  GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
   
Exenatide (Byetta)
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 2

Injection

 
Link  Link to table of independent reviews
Link  MRHA warning on risk of acute pancreatitis and renal failure (2014)
Link  GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
   
Exenatide prolonged release (Bydureon)
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 2

Vial, Pen

 
Link  Link to reviews
Link  NICE TAG 248- MR exenatide
Link  Pancreatic problems with GLP-1 medicines - MHRA statement 2014
Link  GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
   
Liraglutide (Victoza)
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 2

Injection as 6mg/ml prefilled pen

  • Amber 2 - Specialist initiation for the treatment of diabetes in line with Nottinghamshire APC diabetes treatment guidelines.
  • Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity
  • Restricted to dose of 1.2mg only (1.8mg dose is non-formulary and classified grey, Nov 18 APC)
  • Use for the treatment of obesity is non-formulary and classified grey (no formal assessment).
 
Link  Click here for independent reviews
Link  GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
   
Semaglutide (Ozempic)
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 2

Subcutaneous injection as a 4-dose pre-filled pen.

 
   
06.01.02.03  Expand sub section  Meglitinides to top
06.01.02.03  Expand sub section  SGLT2 inhibitors
06.01.02.03  Expand sub section  Thiazolidinediones
 ....
 Non Formulary Items
Lixisenatide+ insulin glargine  (Suliqua)

View adult BNF View SPC online View childrens BNF
Non Formulary
Grey

No formal assessment

 
Semaglutide oral  (Rybelsus)

View adult BNF View SPC online View childrens BNF
Non Formulary
Grey

No formal assessment

 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Grey

Grey / Non-Formulary: Medicines, which the Nottinghamshire APC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.
Grey / Non-Formulary (undergoing assessment): Work is ongoing and will be reviewed at a future APC meeting.
Grey / Non-Formulary (no formal assessment): APC has not formally reviewed this medicine or indication because it had never been requested for formulary inclusion. Often used for drugs new to market.
  

Red

Medicines which should normally be prescribed by specialists only. eg hospital only.
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
  

Amber 1

Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised.
Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the Nottinghamshire APC.
  

Amber 2

Medicines suitable to be prescribed in primary care / general practice after specialist* recommendation or initiation.
A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust DTCs and approved by the Nottinghamshire APC.
*Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice
  

Amber 3

Primary care/ non specialist may initiate as per APC guideline.
The supporting prescribing guideline must have been agreed by the relevant secondary care trust D&TC(s) and approved by the Nottinghamshire APC.
  

Green

Medicines suitable for routine use within primary care.
Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.   

OTC

  

netFormulary